10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

(Mark One)

x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended		August 31, 2012
or
o	TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from			to
Commission File Number		333-173359
T & G Apothecary, Inc.
(Exact name of registrant as specified in its charter)

Nevada	27-4588540
(State or other jurisdiction of incorporation or organization)	(IRS Employer Identification No.)

3330 South Federal Highway Suite 200, Boynton Beach, Florida	33435
(Address of principal executive offices)	(Zip Code)

(647) 344-5900

(Registrant’s telephone number, including area code)

N/A

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
x	YES	o	NO

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).
	x	YES	o	NO

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a small reporting company.  See the definitions of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer	o		Accelerated filer	o
Non-accelerated filer	o	(Do not check if a smaller reporting company)	Smaller reporting company	x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act
	x	YES	o	NO

APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY

PROCEEDINGS DURING THE PRECEDING FIVE YEARS

Check whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Exchange Act after the distribution of securities under a plan confirmed by a court.
	o	YES	o	NO

APPLICABLE ONLY TO CORPORATE ISSUERS

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

8,700,000 common shares issued and outstanding as of October 17, 2012.

TABLE OF CONTENTS

PART I - FINANCIAL INFORMATION		3
Item 1.	Financial Statements		3
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations		9
Item 3.	Quantitative and Qualitative Disclosures About Market Risk		13
Item 4.	Controls and Procedures		13
PART II – OTHER INFORMATION			14
Item 1.	Legal Proceedings		14
Item 1A.	Risk Factors		14
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds		14
Item 3.	Defaults Upon Senior Securities		14
Item 4.	Mine Safety Disclosures		14
Item 5.	Other Information		14
Item 6.	Exhibits		15
SIGNATURES			16

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

These condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and the SEC instructions to Form 10-Q. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. Operating results for the interim period ended August 31, 2012 are not necessarily indicative of the results that can be expected for the full year.

3

T & G APOTHECARY, INC.
(A Development Stage Company)
Condensed Balance Sheets
ASSETS
	August 31,				February 29,
	2012				2012
CURRENT ASSETS	(unaudited)
Cash		$	11			$	92
Total Current Assets			11				92
TOTAL ASSETS		$	11			$	92
LIABILITIES AND STOCKHOLDERS' DEFICIT
CURRENT LIABILITIES
Accounts payable		$	18,206			$	21,478
Notes payable - related parties			14,229				21,164
Accrued interest payable - related parties			-				2,059
Total Current Liabilities			32,435				44,701
STOCKHOLDERS' DEFICIT
Common stock, 100,000,000 shares authorized
at par value of $0.001; 8,000,000
shares issued and outstanding			8,000				8,000
Additional paid-in capital			16,465				(5,000	)
Deficit accumulated during the development stage			(56,889	)			(47,609	)
Total Stockholders' Deficit			(32,424	)			(44,609	)
TOTAL LIABILITIES AND STOCKHOLDERS'
DEFICIT		$	11			$	92

The accompanying notes are an integral part of these condensed financial statements.

4

T & G APOTHECARY, INC.
(A Development Stage Company)
Condensed Statements of Operations
(Unaudited)
													From Inception
	For the Three			For the Three			For the Six			For the Six			on January 18,
	Months ended			Months ended			Months ended			Months ended			2011 Through
	August 31,			August 31,			August 31,			August 31,			August 31,
	2012			2011			2012			2011			2012
REVENUES	$	-		$	-		$	-		$	-		$	-
OPERATING EXPENSES
General and administrative		81			-			81			77			5,040
Professional fees		1,000			8,869			8,268			15,453			48,860
Total Operating Expenses		1,081			8,869			8,349			15,530			53,900
LOSS FROM OPERATIONS		(1,081	)		(8,869	)		(8,349	)		(15,530	)		(53,900	)
OTHER EXPENSES
Interest expense		(465	)		(771	)		(931	)		(927	)		(2,989	)
Total Other Expenses		(465	)		(771	)		(931	)		(927	)		(2,989	)
PROVISION FOR
INCOME TAXES		-			-			-			-			-
NET LOSS	$	(1,546	)	$	(9,640	)	$	(9,280	)	$	(16,457	)	$	(56,889	)
BASIC AND DILUTED
LOSS PER SHARE	$	(0.00	)	$	(0.00	)	$	(0.00	)	$	(0.00	)	$	(0.00	)
WEIGHTED AVERAGE
NUMBER OF SHARES
OUTSTANDING - BASIC AND DILUTED		8,000,000			8,000,000			8,000,000			8,000,000

The accompanying notes are an integral part of these condensed financial statements.

5

T & G APOTHECARY, INC.
(A Development Stage Company)
Condensed Statements of Cash Flows
							From Inception
	For the Six			For the Six			on January 18,
	Months Ended			Months Ended			2011 Through
	August 31,			August 31,			August 31,
	2012			2011			2012
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$	(9,280	)	$	(16,457	)	$	(56,889	)
Adjustments to reconcile net loss to
net cash used in operating activities:
Expenses paid on Company's behalf
by a related party		6,540			-			9,329
Changes to operating assets and liabilities:
Prepaid expenses		-			2,500			-
Accounts payable		(3,272	)		145			18,206
Accrued interest - related party		931			927			2,990
Net Cash Used in Operating Activities		(5,081	)		(12,885	)		(26,364	)
CASH FLOWS FROM INVESTING ACTIVITIES		-			-			-
CASH FLOWS FROM FINANCING ACTIVITIES
Common stock issued for cash		-			-			3,000
Proceeds from note payable - related party		5,000			-			23,375
Net Cash Provided by Financing Activities		5,000			-			26,375
NET INCREASE (DECREASE) IN CASH
AND CASH EQUIVALENTS		(81	)		(12,885	)		11
CASH AND CASH EQUIVALENTS AT
BEGINNING OF PERIOD		92			16,374			-
CASH AND CASH EQUIVALENTS AT
END OF PERIOD	$	11		$	3,489		$	11
SUPPLEMENTAL DISCLOSURES OF
CASH FLOW INFORMATION
CASH PAID FOR:
Interest	$	-		$	-		$	-
Income Taxes	$	-		$	-		$	-
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Forgiveness of note payable - related party	$	21,465		$	-		$	-

The accompanying notes are an integral part of these condensed financial statements.

6

T & G APOTHECARY, INC.

(A Development Stage Company)

Notes to the Condensed Financial Statements

August 31, 2012 and February 29, 2012

NOTE 1 - CONDENSED FINANCIAL STATEMENTS

The accompanying financial statements have been prepared by the Company without audit.  In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations, and cash flows at August 31, 2012, and for all periods presented herein have been made.

Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted.  It is suggested that these condensed financial statements be read in conjunction with the financial statements and notes thereto included in the Company's February 29, 2012 audited financial statements.  The results of operations for the periods ended August 31, 2012 and August 31, 2011, are not necessarily indicative of the operating results for the full year.

NOTE 2 - GOING CONCERN

The Company's financial statements are prepared using generally accepted accounting principles in the United States of America applicable to a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has not yet established an ongoing source of revenues sufficient to cover its operating costs and allow it to continue as a going concern. The ability of the Company to continue as a going concern is dependent on the Company obtaining adequate capital to fund operating losses until it becomes profitable. If the Company is unable to obtain adequate capital, it could be forced to cease operations.

In order to continue as a going concern, the Company will need, among other things, additional capital resources. Management's plan is to obtain such resources for the Company by obtaining capital from management and significant shareholders sufficient to meet its minimal operating expenses and seeking equity and/or debt financing. However management cannot provide any assurances that the Company will be successful in accomplishing any of its plans.

The ability of the Company to continue as a going concern is dependent upon its ability to successfully accomplish the plans described in the preceding paragraph and eventually secure other sources of financing and attain profitable operations. The accompanying financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

NOTE 3 – SIGNIFICANT ACCOUNTING POLICIES

Basis of Accounting

The Company’s financial statements are prepared using the accrual method of accounting.  The Company has elected a February 28 fiscal year-end.

7

T & G APOTHECARY, INC.

(A Development Stage Company)

Notes to the Condensed Financial Statements

August 31, 2012 and February 29, 2012

NOTE 3 – SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ from those estimates.

Recent Accounting Pronouncements

The Company has evaluated recent accounting pronouncements and their adoption has not had or is not expected to have a material impact on the Company’s financial position or statements.

Reclassification

Certain balances in previously issued financial statements have been reclassified to be consistent with the current period presentation.

NOTE 4 - NOTES PAYABLE RELATED PARTY

On January 19, 2011 the Company entered into a promissory note agreement whereby the Company received $18,475 from a Company director and officer. The note accrues interest at a rate of 10.0% per annum, is unsecured and is due on demand.  On August 21, 2012, this note, plus accrued interest was forgiven in full.  The Company recorded the resulting gain on forgiveness of debt as an equity contribution.

As of August 31, 2012, a related party paid expenses on behalf of the Company in the amount of $9,329 and advanced $5,000 for operating expenses.  This amount, accrued in Notes payable – related party, bears no interest and is due on demand. As of August 31, 2012 and February 29, 2011, the Company had accrued interest payable of $0 and $2,059, respectively.

NOTE 5 – COMMON STOCK

The Company is authorized to issue 100,000,000 common shares at a par value of $0.001 per share.  At August 31, 2012, the Company had issued and outstanding 8,000,000 shares of common stock.  Of the issued and outstanding stock, 5,000,000 shares were issued to the founder of the company as founder shares.  On February 7, 2011, the Company issued 3,000,000 shares of its par value $0.001 common stock for $3,000 cash.

NOTE 6 – SUBSEQUENT EVENTS

On September 21, 2012, the Company entered into letter of intent agreement with Biologix Hair, Inc. (“Biologix”) whereby, if consummated, would result in Biologix exchanging all of its issued and outstanding shares for 26,430,000 restricted common shares of the Company.

On October 15, 2012, the Company issued 700,000 shares of common stock to multiple investors at $0.50 per share in a private placement offering for total proceeds of $350,000.

In accordance with ASC 855-10, Company management reviewed all material events through the date of this report and determined that there are no material subsequent events to report.

8

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Forward-Looking Statements

This quarterly report contains forward-looking statements. These statements relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as "may", "should", "expects", "plans", "anticipates", "believes", "estimates", "predicts", "potential" or "continue" or the negative of these terms or other comparable terminology. These statements are only predictions and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to actual results.

Our unaudited financial statements are stated in United States Dollars (US$) and are prepared in accordance with United States Generally Accepted Accounting Principles. The following discussion should be read in conjunction with our financial statements and the related notes that appear elsewhere in this quarterly report. The following discussion contains forward-looking statements that reflect our plans, estimates and beliefs. Our actual results could differ materially from those discussed in the forward looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed below and elsewhere in this quarterly report.

In this quarterly report, unless otherwise specified, all dollar amounts are expressed in United States dollars. All references to "US$" refer to United States dollars and all references to "common stock" refer to the common shares in our capital stock.

As used in this quarterly report, the terms "we", "us", "our" and "our company" mean T & G Apothecary, Inc. unless otherwise indicated.

Company Overview

We were incorporated on January 17, 2011, as T & G Apothecary, Inc.  The business was founded with a vision of creating a pure, all natural personal care products line for women. Our business plan is to develop and market a 100% USDA certified organic personal care product line for women. 

We are currently in the process of negotiating an agreement with Sensibility Soaps, based in Pennsylvania, to develop our product line containing high quality certified USDA Organic ingredients. We decided to use natural ingredients as an alternative to the synthetic ingredients prevalent in personal care products today. We hope to develop products with only the best ingredients from Sensibility Soaps’ trusted suppliers and we intend to establish formulations using fresh, pure, and safe ingredients that appeal to women.

Our products are inspired by many growing trends, but most specifically consumers seeking new, intriguing, formulations which promote well-being either through the principles of natural therapy, or simply for the pleasure the natural aromas the products will bring. Moreover, there is an increasing awareness among consumers of the benefits in using organic and natural products. We intend to differentiate our products by using 100% USDA Organic ingredients. Unlike many other companies, our use of natural ingredients will not entail using a small portion of natural ingredients to tout the product as “natural.” Our products are created to support optimal benefit to the users by containing ingredients that make a difference.

9

We intend for our products to have the following characteristics:

● Moisturizing, non-irritating, softening, cleansing and nourishing;

● 100% USCA certified organic;

● No synthetic preservatives, colors or fragrances;

● No sodium laureth (lauryl) sulfate to irritate skin (we use coconut oil to lather);

● No petro-chemicals, lanolin or mineral oil.

Current Business

We intend to develop, market and sell five initial products under our women’s care line. We will not manufacture our products in-house; instead we intend to source the work to Sensibility Soaps, a company we feel is well equipped to handle our manufacturing needs. We have not entered into any contracts or agreements with Sensibility Soaps.  We have had trouble finding financing for our

On August 21, 2012, we received resignations from Carolyne S. Johnson and Scott A. Stupprich.  Ms. Johnson resigned as president, chief executive officer, chief financial officer and as a director of our company.  Mr. Stupprich resigned as secretary of our company.  Their resignations were not the result of any disagreements with our company regarding its operations, policies, practices or otherwise.  Concurrently with Ms. Johnson’s and Mr. Stupprich’s resignations, we appointed Lilia Roberts as president, chief executive officer, chief financial officer, secretary, treasurer and as a member to our board of directors, effective August 21, 2012.

On August 21, 2012, Ms. Roberts acquired a total of 5,000,000 shares of our common stock from Ms. Johnson, our former director and officer, for total consideration of $50,000.  The funds used for this share purchase were Ms. Roberts’ personal funds.  At the time of the share purchase, Ms. Roberts’ 5,000,000 shares amounted to approximately 62.5% of our issued and outstanding common stock.  In conjunction with the sale of her shares Ms. Johnson provided us with a release from any debt owed to her by our company. 

On September 21, 2012, we entered into letter of intent agreement with Biologix Hair, Inc. whereby, if consummated, would result in Biologix exchanging all of its issued and outstanding shares for 26,430,000 restricted common shares of our company.

Results of Operations for the Three and Six Months Ended August 31, 2012 and 2011 and Period from January 18, 2011 (inception) to August 31, 2012

The following discussion of our results of operations should be read in conjunction with our unaudited financial statements for the three and six month periods ended August 31, 2012 which are included herein.

Our operating results for the three and six month periods ended August 31, 2012 and 2011 and the period from January 18, 2011 (inception) to August 31, 2012 are summarized as follows:

10

													From January 18, 2011 (Inception)
	Three Months Ended						Six Months Ended						To
	August 31,						August 31,						August 31,
	2012			2011			2012			2011			2012
Revenue	$Nil			$Nil			$Nil			$Nil			Nil
General and administrative		81		Nil				81			77			5,040
Professional fees		1,000			8,869			8,268			15,453			48,860
Other expenses - Interest expense		465			771			931			927			2,989
Net Loss	$	(1,546	)	$	(9,640	)	$	(9,280	)	$	(16,457	)		(56,889	)

We generated no revenue for the period from January 18, 2011 (inception) to August 31, 2012. Our operating expenses during three months ended August 31, 2012 were $1,081compared to $8,869 during the same period ended 2011.  Our operating expenses during six months ended August 31, 2012 were $8,349 compared to $15,530 during the same period ended 2011. Operating expenses for the three and six month periods ended August 31, 2012 consisted primarily of professional fees along with organizational costs and bank charges. We incurred operating expenses of $53,900 for the period from January 18, 2011 (inception) to August 31, 2012. We recorded a net loss of $1,546 for the three months ended August 31, 2012, as compared with $9,640 for the same period ended August 31, 2011, a net loss of $9,280 for the six months ended August 31, 2012, as compared with $16,457 for the same period ended August 31, 2011, and $56,889 for the period from January 18, 2011 (inception) until August 31, 2012.

We anticipate our operating expenses will increase as we implement our business plan. The increase will be attributable to expenses to implement our business plan, and the professional fees to be incurred in connection with our ongoing operating expenses as a reporting company under the Securities Exchange Act of 1934.

Liquidity and Capital Resources

Working Capital

	As of			As of
	August 31, 2012			February 29, 2012
Current Assets	$	11		$	92
Current Liabilities	$	32,435		$	44,701
Working Capital	$	(32,424	)	$	(44,609	)

Cash Flows

	Six Month			Six Month
	Period Ended			Period Ended
	August 31, 2012			August 31, 2011
Cash used for Operating Activities	$	(5,081	)	$	(12,885	)
Cash provided by Financing Activities		5,000		Nil
Cash provided by (used in) Investing Activities	Nil			Nil
Net Increase (Decrease) in Cash and Cash Equivalents	$	(81	)	$	(12,885	)

As of August 31, 2012, we had total current assets of $11 and current liabilities of $32,435. We have a working capital deficit of $32,424 as of August 31, 2012.

11

We used $5,081 in cash for operating activities for the six month period ended August 31, 2012 compared with $12,885 for the same period in 2011. Our net loss of $1,546 and a $3,272 decrease in accounts payable represented all of our negative operating cash flow offset by an increase of $6,540 for expenses paid on our company’s behalf by a related party.

Cash provided by financing activities for the six month period ended August 31, 2012 was $5,000 compared to $Nil for the same period in 2011.

Cash provided by investing activities for the six month period ended August 31, 2012 was $Nil compared to $Nil for the same period in 2011.

On January 19, 2011, we entered into a promissory note agreement whereby we received $18,375 from our former officer and director, Carolyne S. Johnson. The note accrues interest at a rate of 10.0% per annum, is unsecured and is due on demand. As of August 31, 2012, we had accrued interest payable of $2,990. Additionally, $14,329 in company expenses were paid by one of our company’s shareholders on our company’s behalf. This amount accrues no interest and is payable on demand.  On August 21, 2012, in conjunction with the sale of her shares to our officer and director, Lilia Roberts, Ms. Johnson provided us with a release from any debt owed to her by our company.

As of August 31, 2012, we have insufficient cash to operate our business at the current level for the next twelve months and insufficient cash to achieve our business goals. The success of our business plan beyond the next 12 months is contingent upon us obtaining additional financing. We intend to fund operations through debt and/or equity financing arrangements, which may be insufficient to fund our capital expenditures, working capital, or other cash requirements. We do not have any formal commitments or arrangements for the sales of stock or the advancement or loan of funds at this time. There can be no assurance that such additional financing will be available to us on acceptable terms, or at all.

Off Balance Sheet Arrangements

We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to stockholders.

Going Concern

Our financial statements are prepared using generally accepted accounting principles in the United States of America applicable to a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business. We have not yet established an ongoing source of revenues sufficient to cover our operating costs and allow us to continue as a going concern. Our ability to continue as a going concern is dependent on our obtaining adequate capital to fund operating losses until we become profitable. If we are unable to obtain adequate capital, we could be forced to cease operations.

In order to continue as a going concern, we will need, among other things, additional capital resources. Management's plan is to obtain such resources for us by obtaining capital from management and significant shareholders sufficient to meet our minimal operating expenses and seeking equity and/or debt financing. However management cannot provide any assurances that we will be successful in accomplishing any of our plans.

Our ability to continue as a going concern is dependent upon our ability to successfully accomplish the plans described in the preceding paragraph and eventually secure other sources of financing and attain profitable operations. The accompanying financial statements do not include any adjustments that might be necessary if we are unable to continue as a going concern.

12

Critical Accounting Policies

Basis of Accounting

Our company’s financial statements are prepared using the accrual method of accounting. Our company has elected a February 28 fiscal year-end.

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Recent Accounting Pronouncements

Our company has evaluated recent accounting pronouncements and their adoption has not had or is not expected to have a material impact on our company’s financial position or statements.

Reclassification

Certain balances in previously issued financial statements have been reclassified to be consistent with the current period presentation.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

A smaller reporting company is not required to provide the information required by this Item.

Item 4. Controls and Procedures

Management’s Report on Disclosure Controls and Procedures

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports filed under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and forms, and that such information is accumulated and communicated to our management, including our president and chief financial officer (our principal executive officer, principal financial officer and principal accounting officer) to allow for timely decisions regarding required disclosure.

As the end of the quarter covered by this report, we carried out an evaluation, under the supervision and with the participation of our president and chief financial officer (our principal executive officer, principal financial officer and principal accounting officer), of the effectiveness of the design and operation of our disclosure controls and procedures. Based on the foregoing, our president and chief financial officer (our principal executive officer, principal financial officer and principal accounting officer) concluded that our disclosure controls and procedures were not effective in providing reasonable assurance in the reliability of our reports as of the end of the period covered by this quarterly report.

Changes in Internal Control over Financial Reporting

During the period covered by this report there were no changes in our internal control over financial reporting that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

13

PART II – OTHER INFORMATION

Item 1. Legal Proceedings

We know of no material, active or pending legal proceedings against our company, nor are we involved as a plaintiff in any material proceeding or pending litigation. There are no proceedings in which any of our directors, officers or affiliates, or any registered or beneficial shareholder, is an adverse party or has a material interest adverse to our interest.

Item 1A.Risk Factors

A smaller reporting company is not required to provide the information required by this Item.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Defaults Upon Senior Securities

None.

Item 4.            Mine Safety Disclosures

Not applicable.

Item 5.            Other Information

On August 21, 2012, we received resignations from Carolyne S. Johnson and Scott A. Stupprich.  Ms. Johnson resigned as president, chief executive officer, chief financial officer and as a director of our company.  Mr. Stupprich resigned as secretary of our company.  Their resignations were not the result of any disagreements with our company regarding its operations, policies, practices or otherwise.  

Concurrently with Ms. Johnson’s and Mr. Stupprich’s resignations, we appointed Lilia Roberts as president, chief executive officer, chief financial officer, secretary, treasurer and as a member to our board of directors, effective August 21, 2012.

14

Item 6.            Exhibits

Exhibit Number	Description of Exhibit
(3)	Articles of Incorporation and Bylaws
3.1	Articles of Incorporation (incorporated by reference to our Registration Statement on Form S-1 filed on April 7, 2011)
3.2	Bylaws (incorporated by reference to our Registration Statement on Form S-1 filed on April 7, 2011)
(10)	Material Contracts
10.1	Release from Carolyne Johnson dated August 21, 2012 (incorporated by reference to our Current Report on Form 8-K filed on August 22, 2012)
10.2	Share Purchase Agreement dated August 21, 2012 between our company, Carolyne Johnson  and Lilia Roberts (incorporated by reference to our Current Report on Form 8-K filed on August 22, 2012)
10.3	Letter of Intent dated September 21, 2012 between our company and Biologix Hair Inc. (incorporated by reference to our Current Report on Form 8-K filed on September 27, 2012)
(31)	Rule 13a-14(a) / 15d-14(a) Certifications
31.1*	Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 of the Chief Executive Officer and Chief Financial Officer
(32)	Section 1350 Certifications
32.1*	Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 of the Chief Executive Officer and Chief Financial Officer
101**	Interactive Data Files
101.INS	XBRL Instance Document
101.SCH	XBRL Taxonomy Extension Schema Document
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document
101.LAB	XBRL Taxonomy Extension Label Linkbase Document
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document

*

Filed herewith.

**

Furnished herewith. Pursuant to Rule 406T of Regulation S-T, the Interactive Data Files on Exhibit 101 hereto are deemed not filed or part of any registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, are deemed not filed for purposes of Section 18 of the Securities and Exchange Act of 1934, and otherwise are not subject to liability under those sections.

15

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	T & G APOTHECARY, INC.
Date:  October 17, 2012	/s/ Lilia Roberts
	Lilia Roberts
	President, Chief Executive Officer, Chief Financial Officer, Secretary, Treasurer and Director
	(Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)

16

EX-31.1

EXHIBIT 31.1

CERTIFICATION PURSUANT TO

18 U.S.C. ss 1350, AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Lilia Roberts, certify that:

1. I have reviewed this quarterly report on Form 10-Q of T & G Apothecary, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date:  October 17, 2012

/s/ Lilia Roberts

Lilia Roberts

President, Chief Executive Officer, Chief Financial Officer, Secretary, Treasurer and Director

(Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)

EX-32.1

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Lilia Roberts, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) the Quarterly Report on Form 10-Q of T & G Apothecary, Inc. for the period ended August 31, 2012 (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of T & G Apothecary, Inc.

Dated:  October 17, 2012
	/s/ Lilia Roberts
	Lilia Roberts
	President, Chief Executive Officer, Chief Financial Officer, Secretary, Treasurer and Director (Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)
	T & G Apothecary, Inc.

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to T & G Apothecary, Inc. and will be retained by T & G Apothecary, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

XML

Notes Payable Related Party

6 Months Ended

Aug. 31, 2012

Related Party Transactions [Abstract]

NOTES PAYABLE RELATED PARTY

NOTE 4 - NOTES PAYABLE RELATED PARTY

On January 19, 2011 the Company entered into a promissory note agreement whereby the Company received $18,475 from a Company director and officer. The note accrues interest at a rate of 10.0% per annum, is unsecured and is due on demand.  On August 21, 2012, this note, plus accrued interest was forgiven in full.  The Company recorded the resulting gain on forgiveness of debt as an equity contribution.

As of August 31, 2012, a related party paid expenses on behalf of the Company in the amount of $9,329 and advanced $5,000 for operating expenses.  This amount, accrued in Notes payable – related party, bears no interest and is due on demand. As of August 31, 2012 and February 29, 2011, the Company had accrued interest payable of $0 and $2,059, respectively.

XML

Significant Accounting Policies

6 Months Ended

Aug. 31, 2012

Accounting Policies [Abstract]

SIGNIFICANT ACCOUNTING POLICIES

NOTE 3 – SIGNIFICANT ACCOUNTING POLICIES

Basis of Accounting

The Company’s financial statements are prepared using the accrual method of accounting.  The Company has elected a February 28 fiscal year-end.

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ from those estimates.

Recent Accounting Pronouncements

The Company has evaluated recent accounting pronouncements and their adoption has not had or is not expected to have a material impact on the Company’s financial position or statements.

Reclassification

Certain balances in previously issued financial statements have been reclassified to be consistent with the current period presentation.

XML

Condensed Balance Sheets (USD $)	Aug. 31, 2012	Feb. 29, 2012
CURRENT ASSETS
Cash	$ 11	$ 92
Total Current Assets	11	92
TOTAL ASSETS	11	92
CURRENT LIABILITIES
Accounts payable	18,206	21,478
Notes payable - related parties	14,229	21,164
Accrued interest payable - related parties		2,059
Total Current Liabilities	32,435	44,701
STOCKHOLDERS' DEFICIT
Common stock, 100,000,000 shares authorized at par value of $0.001; 8,000,000 shares issued and outstanding	8,000	8,000
Additional paid-in capital	16,465	(5,000)
Deficit accumulated during the development stage	(56,889)	(47,609)
Total Stockholders' Deficit	(32,424)	(44,609)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$ 11	$ 92

XML

Condensed Financial Statements

6 Months Ended

Aug. 31, 2012

Condensed Financial Information Of Parent Company Only Disclosure [Abstract]

CONDENSED FINANCIAL STATEMENTS

NOTE 1 - CONDENSED FINANCIAL STATEMENTS

The accompanying financial statements have been prepared by the Company without audit.  In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations, and cash flows at August 31, 2012, and for all periods presented herein have been made.

Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted.  It is suggested that these condensed financial statements be read in conjunction with the financial statements and notes thereto included in the Company's February 29, 2012 audited financial statements.  The results of operations for the periods ended August 31, 2012 and August 31, 2011, are not necessarily indicative of the operating results for the full year.

XML

Going Concern

6 Months Ended

Aug. 31, 2012

Going Concern [Abstract]

GOING CONCERN

NOTE 2 - GOING CONCERN

The Company's financial statements are prepared using generally accepted accounting principles in the United States of America applicable to a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has not yet established an ongoing source of revenues sufficient to cover its operating costs and allow it to continue as a going concern. The ability of the Company to continue as a going concern is dependent on the Company obtaining adequate capital to fund operating losses until it becomes profitable. If the Company is unable to obtain adequate capital, it could be forced to cease operations.

In order to continue as a going concern, the Company will need, among other things, additional capital resources. Management's plan is to obtain such resources for the Company by obtaining capital from management and significant shareholders sufficient to meet its minimal operating expenses and seeking equity and/or debt financing. However management cannot provide any assurances that the Company will be successful in accomplishing any of its plans.

The ability of the Company to continue as a going concern is dependent upon its ability to successfully accomplish the plans described in the preceding paragraph and eventually secure other sources of financing and attain profitable operations. The accompanying financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

XML

Condensed Balance Sheets (Parenthetical) (USD $)	Aug. 31, 2012	Feb. 29, 2012
Statement Of Financial Position [Abstract]
Common stock, shares authorized	100,000,000	100,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares issued	8,000,000	8,000,000
Common stock, shares outstanding	8,000,000	8,000,000

XML

Document and Entity Information	6 Months Ended
	Aug. 31, 2012	Oct. 17, 2012
Document and Entity Information [Abstract]
Entity Registrant Name	T & G APOTHECARY INC
Entity Central Index Key	0001510775
Document Type	10-Q
Document Period End Date	Aug. 31, 2012
Amendment Flag	false
Current Fiscal Year End Date	--02-28
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2013
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		8,700,000

XML

Condensed Statements of Operations (Unaudited) (USD $)	3 Months Ended		6 Months Ended		19 Months Ended
	Aug. 31, 2012	Aug. 31, 2011	Aug. 31, 2012	Aug. 31, 2011	Aug. 31, 2012
Income Statement [Abstract]
REVENUES
OPERATING EXPENSES
General and administrative	81		81	77	5,040
Professional fees	1,000	8,869	8,268	15,453	48,860
Total Operating Expenses	1,081	8,869	8,349	15,530	53,900
LOSS FROM OPERATIONS	(1,081)	(8,869)	(8,349)	(15,530)	(53,900)
OTHER EXPENSES
Interest expense	(465)	(771)	(931)	(927)	(2,989)
Total Other Expenses	(465)	(771)	(931)	(927)	(2,989)
PROVISION FOR INCOME TAXES
NET LOSS	$ (1,546)	$ (9,640)	$ (9,280)	$ (16,457)	$ (56,889)
BASIC AND DILUTED LOSS PER SHARE	$ 0.00	$ 0.00	$ 0.00	$ 0.00	$ 0.00
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING - BASIC AND DILUTED	8,000,000	8,000,000	8,000,000	8,000,000

XML

Significant Accounting Policies (Policies)

6 Months Ended

Aug. 31, 2012

Accounting Policies [Abstract]

Basis of Accounting

Basis of Accounting

The Company’s financial statements are prepared using the accrual method of accounting.  The Company has elected a February 28 fiscal year-end.

Use of Estimates

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ from those estimates.

Recent Accounting Pronouncements

Recent Accounting Pronouncements

The Company has evaluated recent accounting pronouncements and their adoption has not had or is not expected to have a material impact on the Company’s financial position or statements.

Reclassification

Reclassification

Certain balances in previously issued financial statements have been reclassified to be consistent with the current period presentation.

XML

Subsequent Events

6 Months Ended

Aug. 31, 2012

Subsequent Events [Abstract]

SUBSEQUENT EVENTS

NOTE 6 – SUBSEQUENT EVENTS

On September 21, 2012, the Company entered into letter of intent agreement with Biologix Hair, Inc. (“Biologix”) whereby, if consummated, would result in Biologix exchanging all of its issued and outstanding shares for 26,430,000 restricted common shares of the Company.

On October 15, 2012, the Company issued 700,000 shares of common stock to multiple investors at $0.50 per share in a private placement offering for total proceeds of $350,000.

In accordance with ASC 855-10, Company management reviewed all material events through the date of this report and determined that there are no material subsequent events to report.

XML

Subsequent Events (Details) (USD $)	1 Months Ended
	Oct. 31, 2012	Sep. 21, 2012
Subsequent Events (Textual)
Issued and outstanding shares of Biologix exchanged with restricted common shares of company		26,430,000
Number of shares issued of common stock	700,000
Per share value of issued common stock	$ 0.50
Proceeds from issuance of Private Placement Offering	$ 350,000

XML

Notes Payable Related Party (Details) (USD $)	1 Months Ended	6 Months Ended		19 Months Ended
	Jan. 31, 2011	Aug. 31, 2012	Aug. 31, 2011	Aug. 31, 2012	Feb. 29, 2012
Notes Payable Related Party (Textual)
Proceeds from promissory note-related party	$ 18,475
Promissory note agreement date		Jan. 19, 2011
Interest rate on promissory note	10.00%
Expenses paid on Company's behalf by a related party		6,540		9,329
Advances from related party for operating expenses		5,000		5,000
Accrued interest payable - related parties					$ 2,059

XML

Common Stock (Details) (USD $)	1 Months Ended	6 Months Ended
	Feb. 28, 2011	Aug. 31, 2012	Feb. 29, 2012
Common Stock (Textual)
Common stock, par value		$ 0.001	$ 0.001
Common stock, shares authorized		100,000,000	100,000,000
Common stock, shares issued		8,000,000	8,000,000
Common stock, shares outstanding		8,000,000	8,000,000
Shares issued to founder, (Shares)		5,000,000
Shares issued for cash	$ 3,000
Shares issued for cash, (Shares)	3,000,000

XML

Condensed Statements of Cash Flows (USD $)	6 Months Ended		19 Months Ended
	Aug. 31, 2012	Aug. 31, 2011	Aug. 31, 2012
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (9,280)	$ (16,457)	$ (56,889)
Adjustments to reconcile net loss to net cash used in operating activities:
Expenses paid on Company's behalf by a related party	6,540		9,329
Changes to operating assets and liabilities:
Prepaid expenses		2,500
Accounts payable	(3,272)	145	18,206
Accrued interest - related party	931	927	2,990
Net Cash Used in Operating Activities	(5,081)	(12,885)	(26,364)
CASH FLOWS FROM INVESTING ACTIVITIES
CASH FLOWS FROM FINANCING ACTIVITIES
Common stock issued for cash			3,000
Proceeds from note payable - related party	5,000		23,375
Net Cash Provided by Financing Activities	5,000		26,375
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	(81)	(12,885)	11
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	92	16,374
CASH AND CASH EQUIVALENTS AT END OF PERIOD	11	3,489	11
CASH PAID FOR:
Interest
Income Taxes
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Forgiveness of note payable - related party	$ 21,465

XML

Common Stock

6 Months Ended

Aug. 31, 2012

Equity [Abstract]

COMMON STOCK

NOTE 5 – COMMON STOCK

The Company is authorized to issue 100,000,000 common shares at a par value of $0.001 per share.  At August 31, 2012, the Company had issued and outstanding 8,000,000 shares of common stock.  Of the issued and outstanding stock, 5,000,000 shares were issued to the founder of the company as founder shares.  On February 7, 2011, the Company issued 3,000,000 shares of its par value $0.001 common stock for $3,000 cash.